BJ 019
Alternative Names: BJ-019Latest Information Update: 28 Aug 2026
At a glance
- Originator BJ Bioscience
- Class Anti-infectives; Bispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders; Infections
Highest Development Phases
- No development reported Autoimmune disorders; Infections
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for preclinical development in Autoimmune-disorders in China (Parenteral)
- 28 Aug 2026 No recent reports of development identified for preclinical development in Infections in China (Parenteral)
- 05 Jul 2022 BJ 019 is available for licensing in World as of 05 Jul 2022. https://www.bjbioscience.com/en/expand#block-body-2